Capsomer vaccines protect mice from vaginal challenge with human papillomavirus

PLoS One. 2011;6(11):e27141. doi: 10.1371/journal.pone.0027141. Epub 2011 Nov 1.

Abstract

Capsomers were produced in bacteria as glutathione-S-transferase (GST) fusion proteins with human papillomavirus type 16 L1 lacking the first nine and final 29 residues (GST-HPV16L1Δ) alone or linked with residues 13-47 of HPV18, HPV31 and HPV45 L2 in tandem (GST-HPV16L1Δ-L2x3). Subcutaneous immunization of mice with GST-HPV16L1Δ or GST-HPV16L1Δ-L2x3 in alum and monophosphoryl lipid A induced similarly high titers of HPV16 neutralizing antibodies. GST-HPV16L1Δ-L2x3 also elicited moderate L2-specific antibody titers. Intravaginal challenge studies showed that immunization of mice with GST-HPV16 L1Δ or GST-HPV16L1Δ-L2x3 capsomers, like Cervarix®, provided complete protection against HPV16. Conversely, vaccination with GST-HPV16 L1Δ capsomers failed to protect against HPV18 challenge, whereas mice immunized with either GST-HPV16L1Δ-L2x3 capsomers or Cervarix® were each completely protected. Thus, while the L2-specific response was moderate, it did not interfere with immunity to L1 in the context of GST-HPV16L1Δ-L2x3 and is sufficient to mediate L2-dependent protection against an experimental vaginal challenge with HPV18.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / immunology
  • Capsid / chemistry*
  • Capsid / immunology
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Human papillomavirus 16 / genetics*
  • Human papillomavirus 16 / immunology
  • Humans
  • Immunization
  • Mice
  • Mice, Inbred BALB C
  • Papillomaviridae / pathogenicity*
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Vaccines / therapeutic use*
  • Vagina / immunology
  • Vagina / virology*
  • Virion*

Substances

  • Antibodies, Neutralizing
  • Papillomavirus Vaccines